Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025; H.R. 9504, Tax Exempt Hospital Transparency Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Issues related to DTC advertising regulations Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act Issues pertaining to prior authorization - HR 9396, Prior Authorization Accountability Act Issues pertaining to transparency - HR 9393, Lower Costs, More Transparency Act
Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations Issues pertaining to prior authorization - HR 3514, Improving Seniors Timely Access to Care Act
Tariffs on pharmaceutical products